Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07341737). This is a study registration, not published results. Lead sponsor: Second Life Therapeutics. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell), Esophageal Cancer, Stomach (Gastric) Cancer, Liver Cancer, Intestinal Cancer, Bladder Cancer, Renal Cancer, Prostate Cancer, Melanoma (Skin Cancer), Breast Cancer, Ovarian Cancer, Endometrial Cancer, Colorectal Cancer. Interventions: BIOLOGICAL: SL-28; BIOLOGICAL: SL-28; BIOLOGICAL: SL-28. Primary outcome measures: Number of participants with treatment-emergent adverse events , 12 weeks; To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion. , 12 weeks; Change from baseline in ECG QT interval , 12 weeks; Change from baseline in vital signs , 12 weeks; Change from baseline in vital signs , 12 weeks; Change from baseline in vital signs , 12 weeks; Number of participants with dose-limiting toxicities (DLTs) , 12 weeks. Brief summary: Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.